Avecho Biotechnology Limited (ASX:AVE)
0.0100
+0.0010 (11.11%)
At close: Mar 4, 2026
Avecho Biotechnology Revenue
In the year 2025, Avecho Biotechnology had annual revenue of 1.24M AUD with 9.28% growth. Avecho Biotechnology had revenue of 677.69K in the half year ending December 31, 2025, with 2,399.61% growth.
Revenue
1.24M
Revenue Growth
+9.28%
P/S Ratio
26.71
Revenue / Employee
82.52K
Employees
15
Market Cap
33.06M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.24M | 105.09K | 9.28% |
| Dec 31, 2024 | 1.13M | 659.12K | 139.19% |
| Dec 31, 2023 | 473.55K | -655.71K | -58.07% |
| Dec 31, 2022 | 1.13M | 335.66K | 42.30% |
| Dec 31, 2021 | 793.60K | 408.97K | 106.33% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EZZ Life Science Holdings | 61.40M |
| Neurotech International | 7.07M |
| Neurizon Therapeutics | 5.98M |
| Amplia Therapeutics | 5.01M |
| Proteomics International Laboratories | 3.21M |
| Noxopharm | 2.68M |
| Entropy Neurodynamics | 1.58M |
| Argenica Therapeutics | 1.01M |